Literature DB >> 28793134

Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma.

Jordan M Cloyd1, Matthew H G Katz1, Huamin Wang2, Amanda Cuddy1, Y Nancy You1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28793134      PMCID： PMC5831418          DOI： 10.1001/jamasurg.2017.2631

Source DB:  PubMed          Journal:  JAMA Surg        ISSN： 2168-6254            Impact factor:   14.766


× No keyword cloud information.
  6 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

3.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Authors:  John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler
Journal:  JAMA       Date:  2010-09-08       Impact factor: 56.272

Review 4.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

5.  Prognostic value of microsatellite instability in resectable pancreatic cancer.

Authors:  Bunzo Nakata; Yan Qing Wang; Masakazu Yashiro; Nobuaki Nishioka; Hiroaki Tanaka; Masaichi Ohira; Tetsuro Ishikawa; Hiroji Nishino; Kosei Hirakawa
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

6.  Risk of pancreatic cancer in families with Lynch syndrome.

Authors:  Fay Kastrinos; Bhramar Mukherjee; Nabihah Tayob; Fei Wang; Jennifer Sparr; Victoria M Raymond; Prathap Bandipalliam; Elena M Stoffel; Stephen B Gruber; Sapna Syngal
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272
  6 in total
  8 in total

Review 1.  Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.

Authors:  Laura D Wood; Marcia Irene Canto; Elizabeth M Jaffee; Diane M Simeone
Journal:  Gastroenterology       Date:  2022-04-07       Impact factor: 33.883

2.  Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer.

Authors:  Deena M A Gendoo; Robert E Denroche; Amy Zhang; Nikolina Radulovich; Gun Ho Jang; Mathieu Lemire; Sandra Fischer; Dianne Chadwick; Ilinca M Lungu; Emin Ibrahimov; Ping-Jiang Cao; Lincoln D Stein; Julie M Wilson; John M S Bartlett; Ming-Sound Tsao; Neesha Dhani; David Hedley; Steven Gallinger; Benjamin Haibe-Kains
Journal:  PLoS Comput Biol       Date:  2019-01-10       Impact factor: 4.475

3.  Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.

Authors:  Saori Mishima; Hiroya Taniguchi; Kiwamu Akagi; Eishi Baba; Yutaka Fujiwara; Akira Hirasawa; Masafumi Ikeda; Osamu Maeda; Kei Muro; Hiroshi Nishihara; Hiroyki Nishiyama; Tadao Takano; Katsuya Tsuchihara; Yasushi Yatabe; Yasuhiro Kodera; Takayuki Yoshino
Journal:  Int J Clin Oncol       Date:  2019-07-08       Impact factor: 3.402

Review 4.  Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer.

Authors:  Michele Ghidini; Andrea Lampis; Milko B Mirchev; Ali Fuat Okuducu; Margherita Ratti; Nicola Valeri; Jens C Hahne
Journal:  Genes (Basel)       Date:  2020-12-29       Impact factor: 4.096

5.  Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.

Authors:  Gokce Askan; Ibrahim Halil Sahin; Joanne F Chou; Aslihan Yavas; Marinela Capanu; Christine A Iacobuzio-Donahue; Olca Basturk; Eileen M O'Reilly
Journal:  BMC Cancer       Date:  2021-04-09       Impact factor: 4.430

Review 6.  The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship.

Authors:  Irem Sahin; Sevda Turen; Pranav Santapuram; Ibrahim Halil Sahin
Journal:  Cancer Drug Resist       Date:  2020-09-04

Review 7.  Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers.

Authors:  Martina Amato; Renato Franco; Gaetano Facchini; Raffaele Addeo; Fortunato Ciardiello; Massimiliano Berretta; Giulia Vita; Alessandro Sgambato; Sandro Pignata; Michele Caraglia; Marina Accardo; Federica Zito Marino
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

Review 8.  Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.

Authors:  Dimitrios Giannis; Dimitrios Moris; Andrew S Barbas
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.